Parkinson’s disease, affecting over a million individuals in the United States alone and millions more worldwide, manifests with symptoms ranging from tremors and motor impairments to cognitive decline, sleep disturbances, and motivational deficits. Traditionally, therapies have targeted symptomatic relief, typically through life-long pharmacological regimens or deep brain stimulation (DBS), which employs invasive electrode implantation. However, while alleviating some symptoms, these approaches fall short of halting or reversing disease progression. The new study shifts the paradigm by pinpointing the SCAN as the neurological epicenter and offering innovative, non-invasive therapeutic options.

The SCAN, first described by researchers at Washington University School of Medicine in 2023, resides within the motor cortex — the brain’s command center for voluntary movement. This network is crucial for transforming cognitive action plans into physical movements while simultaneously integrating sensory feedback to refine execution. Given the complexity and multifaceted symptoms of Parkinson’s, researchers hypothesized that SCAN dysfunction might explain the broader symptom spectrum beyond motor control, encompassing cognitive and autonomic functions.

To test this hypothesis, the research consortium led by Changping Laboratory in China collaborated closely with Washington University in St. Louis and other institutions. They amassed brain imaging data from more than 800 participants, spanning different therapeutic modalities including DBS, transcranial magnetic stimulation (TMS), focused ultrasound, and pharmacological treatments, alongside healthy controls and individuals with other movement disorders. This large dataset enabled a comprehensive network analysis that revealed Parkinson’s-related pathology as characterized by an aberrant hyperconnectivity between SCAN and the brain’s subcortical regions while other neurodegenerative disorders did not demonstrate this pattern.

The hyperconnectivity between SCAN and subcortical structures — areas responsible for emotion, memory, and motor regulation — disrupts the normal orchestration of motor and cognitive functions that Parkinson’s patients suffer. This abnormal neural wiring does not only cause the classic motor impairments traditionally linked to Parkinson’s but also impairs associated cognitive processes and bodily functions, broadening the disease’s impact beyond prior conceptions. This insight reconceptualizes Parkinson’s as a disorder of broader somato-cognitive network dysfunction rather than isolated basal ganglia pathology.

Building on these insights, researchers devised a highly precise neuromodulation strategy leveraging advanced TMS technology. This non-invasive technique applies targeted magnetic pulses across the scalp to modulate neuronal activity with millimeter spatial accuracy. In clinical trials, transcranial magnetic stimulation focused specifically on SCAN regions more than doubled symptom improvement compared to stimulation of adjacent brain areas not directly associated with the network. Over two weeks, 56% of patients who received SCAN-targeted TMS exhibited meaningful clinical improvement, a compelling contrast to the 22% response rate in the control group.

The implications of these findings are profound; they demonstrate for the first time that precision neuromodulation of a finely defined network can markedly enhance therapeutic efficacy in Parkinson’s treatment while avoiding the risks of surgical interventions like DBS. Moreover, because TMS is non-invasive, it opens avenues for earlier intervention in the disease course, potentially slowing or even reversing progression rather than solely managing symptoms in advanced stages.

This discovery is just the beginning. Researchers underscore the need for further basic and translational studies to elucidate how distinct SCAN components relate to specific Parkinsonian symptoms. Such dissected understanding will pave the way for even more specialized and personalized interventions that can address the heterogeneous clinical presentations of Parkinson’s disease. The team is actively planning additional clinical trials employing other cutting-edge neuromodulation methods, such as low-intensity focused ultrasound, which uses acoustic energy to remotely and non-invasively modulate brain circuitry.

Further advancing clinical possibilities, co-author Dr. Nico Dosenbach, a co-founder of Turing Medical — a startup spun out of Washington University — is developing surface electrode strip technologies for targeted neuromodulation of SCAN regions to improve gait dysfunction in Parkinson’s. Partnering novel technology development with translational clinical research reflects a paradigm of precision medicine aiming for high-impact, scalable, and patient-friendly therapies.

This landmark study exemplifies how the convergence of multi-institutional collaboration, advanced neuroimaging, network neuroscience, and innovative therapeutic technologies can break new ground in understanding and treating complex neurological diseases. By reframing Parkinson’s disease as a disorder of the somato-cognitive action network, the researchers have opened an exciting new chapter that promises to transform future management strategies and offer renewed hope for millions worldwide.

Subject of Research: People

Article Title: Parkinson’s disease as a somato-cognitive action network disorder

News Publication Date: 4-Feb-2026

Web References: DOI: 10.1038/s41586-025-10059-1

References:
Ren J, Zhang W, Dahmani L, Gordon EM, Li S, Zhou Y, Long Y, Huang J, Zhu Y, Guo N, Jiang C, Zhang F, Bai Y, Wei W, Wu Y, Bush A, Vissani M, Wei L, Oehrn CR, Morrison MA, Zhu Y, Zhang C, Hu Q, Yin Y, Cui W, Fu X, Zhang P, Wang W, Ji GJ, Wang K, Wang Z, Kimberley T, Little S, Starr PA, Richardson RM, Li L, Wang M, Wang D, Dosenbach NUF, Liu H. Parkinson’s disease as a somato-cognitive action network disorder. Nature. Feb. 4, 2026.

Image Credits: Sara Moser/WashU Medicine

Keywords: Parkinson’s disease, Neurological disorders, Neurology, Brain stimulation

Parkinson’s disease, characterized by tremors, bradykinesia, rigidity, and postural instability, severely impairs motor function, diminishing quality of life. While STN-DBS is a well-established surgical intervention that improves motor symptoms by delivering electrical impulses to specific brain regions, its effects on axial symptoms—such as gait disturbances and balance problems—have been inconsistent. The variability in therapeutic outcomes has puzzled clinicians and researchers alike, prompting a deeper dive into the genetic underpinnings that might influence treatment responsiveness.

Enter the GBA1 gene—a critical player in lysosomal function encoding the enzyme glucocerebrosidase. Mutations in GBA1 are among the most common genetic risk factors for PD, linked to earlier disease onset and a more aggressive course, notably with pronounced cognitive decline and axial motor impairments. Despite this knowledge, the intersection between GBA1 genotype and STN-DBS outcomes remained elusive until now. The research team led by Bove et al. conducted an extensive analysis to fill this knowledge gap.

The study enrolled a sizable cohort of PD patients undergoing STN-DBS, stratified based on their GBA1 genotype status. By meticulously comparing axial motor responses pre- and post-surgery, researchers uncovered a striking pattern: individuals harboring GBA1 mutations exhibited a significantly diminished improvement, or even worsening, in axial symptoms following STN-DBS, contrasting sharply with the robust benefits seen in non-carriers.

To ensure the robustness of their findings, the authors employed rigorous motor scoring systems, including the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) axial subscore assessments, complemented by objective gait and postural stability measures. This multimodal approach solidified the link between GBA1 genotype and suboptimal axial symptom response, highlighting a gene-dependent variance in therapeutic outcomes hitherto underappreciated.

What makes this discovery particularly compelling is that it challenges the conventional one-size-fits-all paradigm in PD treatment. The insight that a single genetic mutation can modulate responsiveness to a highly targeted neuromodulation technique underscores the urgent need for incorporating genetic screening into clinical decision-making processes. For patients with GBA1 mutations, alternative or adjunctive therapies may be necessary to address axial deterioration effectively.

Moreover, the study delves into potential pathological mechanisms driving this genotype-linked differential response. The GBA1 mutation impairs lysosomal degradation pathways, leading to aberrant accumulation of alpha-synuclein—a hallmark of PD pathology. This pathological cascade likely impacts neural circuits differently, possibly affecting the subthalamic nucleus and its connectivity, thereby altering the neuromodulatory effects of DBS. Future research focusing on synaptic and network alterations in GBA1 mutation carriers could illuminate these mechanistic underpinnings further.

The implications of this study extend beyond clinical practice to the sphere of therapeutic development. Pharmaceutical companies and biotechnology firms investing in neuromodulation technologies and gene-targeted therapies might now consider stratifying trial cohorts by genetic markers such as GBA1. This stratification could refine efficacy outcomes and hasten the development of precision interventions, mitigating risks of treatment failure and adverse effects.

Equally important is the potential psychosocial impact of these findings. Patients and caregivers grappling with the uncertainties of Parkinson’s disease management could benefit from more accurate prognostic information regarding DBS outcomes. Genetic counseling integrated with neurologic care creates an avenue for more informed consent discussions, realistic expectation setting, and tailored supportive care strategies, ultimately enhancing patient empowerment.

Another dimension of this research worth highlighting is its methodological excellence. The multi-center design, incorporating diverse patient populations, enhances the generalizability of findings across different demographics and clinical settings. Additionally, the longitudinal follow-up provides valuable insights into the durability of DBS effects in relation to genetic background, an aspect often neglected in prior studies with shorter observation windows.

The visual data presented in the study reinforce the textual findings with compelling clarity. Graphical representations demonstrate clear divergence in axial symptom trajectories post-DBS between GBA1 mutation carriers and non-carriers, reinforcing the narrative of genotype-driven response heterogeneity. Such visualization aids clinicians in conceptualizing the expected clinical course and customizing patient monitoring protocols accordingly.

While this study focuses explicitly on axial motor symptoms, the concept of genotype-influenced neuromodulation response invites speculation about other non-motor domains affected by Parkinson’s disease, such as cognition, mood, and autonomic function. Future investigations are warranted to assess whether GBA1 and other genetic factors similarly modulate these dimensions, potentially broadening the scope of personalized therapeutic strategies.

In light of these compelling findings, the authors advocate for the routine incorporation of GBA1 genotyping in the pre-surgical evaluation of PD patients considered for STN-DBS. Such integration promises to optimize patient selection, minimize futile surgical interventions, and align treatment plans with the emerging ethos of precision neurology. Furthermore, the establishment of genotype-specific DBS programming parameters could emerge as a novel frontier in maximizing clinical benefit.

The ramifications of this research resonate deeply within the neurological community, spearheading a paradigm shift from uniform treatment algorithms toward an era where genetics guide clinical pathways. The meticulous work of Bove and colleagues exemplifies how translational research can bridge molecular genetics with interventional therapeutics, bringing precision medicine from the bench to the bedside.

As we move forward, collaboration between neurologists, geneticists, neurosurgeons, and rehabilitation specialists will be imperative to harness the full potential of these findings. Multidisciplinary approaches integrating genetic insights with advanced neurotechnology hold the promise to transform the landscape of Parkinson’s disease care, improving outcomes and quality of life for thousands worldwide.

This study not only opens avenues for refining surgical therapies but also emphasizes the importance of continuous genetic research in neurodegeneration. Comprehensive genetic profiling, coupled with deep phenotyping and sophisticated neuromodulatory techniques, may ultimately unlock customized therapeutic regimens that transcend traditional boundaries, fostering hope for tailored and effective interventions in Parkinson’s disease and beyond.

In summary, unraveling the role of GBA1 genotype in the response of axial signs to subthalamic nucleus deep brain stimulation marks a pivotal advancement in Parkinson’s research. By elucidating the genetic determinants of treatment efficacy, this study paves the way for personalized neurosurgical interventions, heralding a new chapter where genetics inform clinical decisions and empower patient-specific care strategies.

Subject of Research: The influence of GBA1 genotype on axial motor symptom response to subthalamic nucleus deep brain stimulation in Parkinson’s disease.

Article Title: Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation.

Article References:
Bove, F., Genovese, D., De Biase, A. et al. Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation. npj Parkinsons Dis. 11, 296 (2025). https://doi.org/10.1038/s41531-025-01140-7

Image Credits: AI Generated